Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Phase 2 Trials

New Brunswick, New Jersey

Phase 2 colorectal cancer trials in New Brunswick, NJ

6 Phase 2 colorectal cancer studies are recruiting participants at sites in New Brunswick as of November 18, 2026, according to ClinicalTrials.gov. Colorectal Phase 2 Trials can help you understand your options and connect with a study team.

Call (888) 467-9061
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

New Brunswick at a glance

  • 6 studies are recruiting at a site in New Brunswick.
  • By phase: Phase 2 (6).
  • By sponsor: university, hospital or other (4), industry (2).
  • Most recent update to one of these records: November 5, 2026.

Studies recruiting in New Brunswick

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Dustin Deming
    Study site
    Rutgers Cancer Institute of New Jersey
    Registry record
    NCT06493019 · updated
  2. FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Oncolytics Biotech
    Study site
    Rutgers Cancer Institute
    Registry record
    NCT07446322 · updated
  3. E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Christian Hinrichs
    Study sites
    RWJBarnabas Health - Robert Wood Johnson University Hospital · Rutgers Cancer Institute
    Registry record
    NCT05686226 · updated
  4. A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Criterium, Inc.
    Study site
    Rutgers Cancer Institute
    Registry record
    NCT06992258 · updated
  5. Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Rutgers, The State University of New Jersey
    Study sites
    RWJBarnabas Health - Robert Wood Johnson University Hospital · Rutgers Cancer Institute of New Jersey
    Registry record
    NCT05806931 · updated
  6. Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Howard S. Hochster, MD
    Study sites
    Robert Wood Johnson University Hospital · Rutgers Cancer Institute of New Jersey
    Registry record
    NCT05296681 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in New Brunswick, NJ on ClinicalTrials.gov.

Ask about studies near New Brunswick

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in New Jersey

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 2, as each study is coded in the registry.

Colorectal Phase 2 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 467-9061

or send a short form

How should we reach you?

Call